

Next Generation Undruggable 2022

Boston, MA, Tuesday, October 11th 2022

Tuesday, October 11th 2022

9:00AM ET Chair's Opening Remarks & Setting the Scene

- A look at what will be covered - what will be the key learning outcomes of the day?

Adrian Gill, Senior Vice President Discovery Chemistry, [Revolution Medicines](#)

9:10AM ET Keynote Presentation: Delivered by a Representative of Phoremost

Benedict Cross, Chief Technology Officer, [Phoremost Ltd](#)

The logo for Phoremost, featuring the word "PHOREMOST" in a bold, sans-serif font. The letters "PHORE" are in white, and "MOST" is in red. A stylized red and white circular graphic element is positioned between the "O" and "M". The logo is set against a dark blue rectangular background.

9:35AM ET Case Study: Leveraging Fragment Based Drug Discovery for Undruggable Targets

- Fragment to clinic case study.
- New technologies in FBDD, including cryoEM.
- Future FBDD challenges.

Nicola Wilshire, Vice President of DMPK and Preclinical Development, [Astex Pharmaceuticals](#)

9:55AM ET Keynote Panel Discussion with Open Q&A: Lessons Learned from the First Wave of Drugging the Undruggable

With the extensive history and previous difficulties in the field of “undruggable diseases” we have gained a wealth of experience from the mistakes and challenges of the past. This panel aims to highlight the obstacles of previous research in order to have a greater rate of success in the future.

- What were the key lessons learned from previous ventures into drugging the undruggable?
- What makes this field of research so difficult?
- How can we overcome the challenges and difficulties of the past?
- How can we increase efficiency in the discovery of new drugs?
- What are the most promising new approaches in undruggable research?

Christian Dillon, Chief Scientific Officer, [Phoremot Ltd](#)



Uli Stilz, Vice President, [Novo Nordisk Bio Innovation Hub](#)

Greg Verdine, Founder, President and CEO, [FogPharma/ LifeMine Therapeutics](#)

Pascal Fortin, Chief Scientific Officer, [Relay Therapeutics](#)

Maria Van Dongen, Head of External Innovation, Therapeutics Discovery, [The Janssen Pharmaceutical Companies of Johnson & Johnson](#)

Stephen Fawell, VP Head Oncology Discovery, [AstraZeneca](#)

10:40AM -11:25AM ET Morning Refreshments & Speed Networking

11:25AM ET Case Study: Unlocking Oncogenes with Covalent Approaches

- History of the relationship between oncology and covalent molecules
- The first highly specific covalent molecule against the most mutated oncogene in cancer (PI3K-alpha)
- Tools involved in finding new covalent drugs

Neil Dhawan, Chief Executive Officer, [Totus Medicines](#)

11:45AM ET Case Study: Drugging the Next Wave of Oncology Targets: Precision Oncology 2.0

- Integrating and optimizing discovery technologies to drug next generation targets in oncology
- Defining the path to discovery for challenging targets
- Leveraging chemical proteomics to target transcription factors

Darrin Stuart, Chief Scientific Officer, [Scorpion Therapeutics](#)

12:05AM ET Presentation: Hit Generation Sciences, the Novartis Approach to Tackle the Undruggable

- HGS combines cutting edge technology platforms with Medicinal Chemistry
- Extensive sampling of chemical space through DNA encoded small molecules and in vitro-translated peptides
- Integration of AI/ML to explore virtual chemical space
- A broad host of modalities allow target and disease tailored hit generation strategies are required

Horst Hemmel, Executive Director Global Discovery Chemistry, [Novartis](#)

12:25PM ET Case Study: Utilizing Oligonucleotides to Upregulate Genes

- Understanding how harnessing regulatory RNA can be used to control gene expression.
- Case example - utilizing oligonucleotides to address haploinsufficient disease
- Determine the future potential of this method.

Josh Mandel-Brehm, Chief Executive Officer, [CAMP4 Therapeutics](#)

12:45PM - 2:00PM ET Lunch & Networking

2:00PM ET

Roundtables

During these intimate breakout sessions, attendees will discuss the key questions involved in drugging the “undruggable”. Through deep-dive discussions, examples and peer-to-peer learning, these interactive roundtable sessions will allow attendees to uncover answers to questions that are not possible through presentations and panels. The topics in these three sessions will remain the same; giving you the opportunity to participate in two sessions. You are spoilt for choice!

<p>Roundtable - Why are Partnerships so Crucial in the Difficult to Drug Field?</p> <ul style="list-style-type: none"> • Why are partnerships and investments so important to drive drug discovery? • Are there any risks associated with forming partnerships? • When is the best time to enter a partnership? <p>Natalia Ulyanova, Business Development Director, Oncology, Astellas Pharma</p> <p>Niels Emmerich, Vice President, Global Head Search & Evaluation, Abbvie</p>	<p>Roundtable - How to Bring Industry Value and Interest to a Next Generation Startup: Science to Scale Up</p> <ul style="list-style-type: none"> • Have your questions answered on how to grow a small biotech • How do you gain interest from investors? • What is the process of scaling up a biotech? 	<p>Roundtable - What is the Impact of AI and Machine Learning Having on Undruggable Research?</p> <ul style="list-style-type: none"> • How can the use of AI & ML help us to accelerate drug discovery? • How can AI & ML technology work to simulate drug and cellular interactions? • What does AI & ML have in store for the future of drug discovery?
--	---	---

2:40PM ET **Time to Switch!**

<p>Roundtable - What is the Impact of AI and Machine Learning Having on Undruggable Research?</p> <ul style="list-style-type: none"> • How can the use of AI & ML help us to accelerate drug discovery? • How can AI & ML technology work to simulate drug and cellular interactions? 	<p>Roundtable - Why are Partnerships so Crucial in the Difficult to Drug Field?</p> <ul style="list-style-type: none"> • Why are partnerships and investments so important to drive drug discovery? • Are there any risks associated with forming partnerships? • When is the best time to enter a partnership? 	<p>Roundtable - How to Bring Industry Value and Interest to a Next Generation Startup: Science to Scale Up</p> <ul style="list-style-type: none"> • Have your questions answered on how to grow a small biotech • How do you gain interest from investors? • What is the process of scaling up a biotech?
--	---	---

<ul style="list-style-type: none"> • What does AI & ML have in store for the future of drug discovery? 	<p>Natalia Ulyanova, Business Development Director, Oncology, Astellas Pharma</p> <p>Niels Emmerich, Vice President, Global Head Search & Evaluation, Abbvie</p>	
---	--	--

3:20PM ET

Afternoon Refreshments & Networking

4:05PM ET Case Study: Application of the ReSOLVE platform to identify druggable pockets and conduct virtual screening in the absence of any known chemical matter

- Learn about novel approaches of advanced protein MD and solvation analysis to rapidly identify novel pockets and pocket conformations
- See/Hear/Review examples of high fidelity virtual screens using ReSOLVE and libraries of billions and potentially trillions of compounds
- Explore a vision for the future to identify pockets and novel chemical matter for difficult-to-drug targets

Mike Crackower, Chief Scientific Officer, [Ventus Therapeutics](#)

4:25PM ET Panel with Open Q&A : First wave and Next Generation Protein Degradation: How has the Exploitation of Protein Degradation Evolved

We all know of protein degradation but where is it heading in the future? This panel will discuss the more well known methods of protein degradation and lessons learned along the way. We will also discover the up and coming, novel approaches and how these can impact the future of undruggable disease as we know it.

- What are the different methods of protein degradation?
- What challenges remain in the field of protein degradation?
- How does the exploitation of protein degradation help us to treat the once undruggable diseases?
- What are the risks of these methods?
- What future effect do these methods have on how we approach undruggable discovery?

Nicki Thompson, Chief Executive Officer, [Amphista Therapeutics](#)

Randy Teel, Senior VP, Corporate & Business Development, [Arvinas](#)

Gwenn Hansen, Chief Scientific Officer, [Nurix Therapeutics](#)

Chris De Savi, Senior Vice President and Head of Drug Discovery, [Kymera Therapeutics](#)

5:25PM ET Chair's Closing Remarks

- Summary of key learnings discussed throughout the day.
- What is the impact on medicine and the future of undruggable research?

Adrian Gill, Senior Vice President Discovery Chemistry, [Revolution Medicines](#)

5:35PM ET Drinks Reception Hosted by Title Partners, Phoremost Ltd

PHOREMOST